Last reviewed · How we verify

NCT04751084

Buscopan in Patients Undergoing IVF/Intracytoplasmic Sperm Injection Treatment

Active, enrolled NA Last updated 8 May 2024
What this trial tests

NA trial testing Buscopan 20 milligrams/ML Injectable Solution in IVF in 675 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
30 May 2020
Primary endpoint
30 April 2024
14 September 2024

Quick facts

Lead sponsorChinese University of Hong Kong
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeprevention
Enrollment675
Start date30 May 2020
Primary completion30 April 2024
Estimated completion14 September 2024
Sites1 location across Hong Kong

Drugs / interventions tested

Conditions studied

Sponsor

Chinese University of Hong Kong

Who can join

Under 42, female only, with IVF or Intracytoplasmic Sperm Injection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine if the use of Buscopan in patients undergoing IVF/ICSI treatment with high uterine contraction frequency prior to embryo transfer has a higher live birth rate.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for IVF

Currently open trials in the same condition.

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04751084.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing